Asenapine Transdermal Patch Suppliers & Bulk Manufacturers
Available Forms: Transdermal Patch
Available Strengths: 3.8 mg/24 hr, 5.7 mg/24 hr, 7.6 mg/24 hr
Reference Brands: Secuado®(US)
Category:
Antipsychotropic Drugs
Asenapine is an atypical antipsychotic that works by antagonizing dopamine D2 and serotonin 5-HT2A receptors, helping to manage symptoms like hallucinations, delusions, and mood instability. The transdermal patch delivers medication steadily through the skin, ensuring consistent blood levels. It is used for the treatment of schizophrenia in adults, especially beneficial for patients who have difficulty with oral medications or require non-invasive, once-daily dosing.
Asenapine Transdermal Patch is available in Transdermal Patch
and strengths such as 3.8 mg/24 hr, 5.7 mg/24 hr, 7.6 mg/24 hr.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Asenapine Transdermal Patch is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Asenapine Transdermal Patch can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
The Asenapine transdermal patch is FDA-approved in the United States (brand name: Secuado) for the treatment of schizophrenia in adults. It is the first and only transdermal antipsychotic approved in the U.S. As of now, it is not approved in the European Union, and marketing would require a new MAA (Marketing Authorization Application) via national or centralized procedures.
Regulatory requirements in the U.S. include GMP-compliant patch manufacturing, transdermal pharmacokinetics, adhesion and skin safety data, and documentation addressing risks like extrapyramidal symptoms and QT prolongation. U.S. labeling includes warnings for elderly dementia-related psychosis.
To explore dossier-ready Asenapine transdermal patches and alternatives, visit Pharmatradz.com — your global B2B pharma sourcing hub.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing